One ring is sufficient to inhibit α-synuclein aggregation

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Parkinson's disease (PD) is a prevalent neurodegenerative disorder marked by dopaminergic neuron loss.
• Lewy bodies, primarily composed of aggregated alpha-synuclein (α-synuclein), are a hallmark of PD.
• Preventing α-synuclein aggregation is a key therapeutic strategy for PD.

Purpose of the Study:

• To investigate the potential of simple aromatic compounds as molecular chaperones against α-synuclein aggregation.
• To explore the structure-activity relationships of these compounds in inhibiting and dismantling α-synuclein fibrils.

Main Methods:

• Screening of small molecules, including dopamine derivatives and gallic acid, for their effect on α-synuclein aggregation.
• Utilizing techniques to assess the inhibition of amyloid fibril formation and the dismantling of mature fibrils.
• Conducting structure-activity relationship analyses to understand the role of functional groups.

Main Results:

• A subset of single aromatic ring compounds effectively blocked α-synuclein assembly into amyloid fibrils.
• These compounds often redirected aggregation towards non-toxic off-pathway oligomers.
• Some compounds demonstrated the ability to disentangle pre-formed α-synuclein amyloid fibrils.

Conclusions:

• Simple aromatic molecules can act as potent molecular chaperones against α-synuclein aggregation.
• These compounds represent promising lead scaffolds for the rational development of Parkinson's disease therapies.
• Understanding their structure-activity relationships can guide the design of more effective disease-modifying drugs.